Signal from the log
TwoStep Therapeutics
62,5 M$ · Series A · United States · Biotech
Biotech de San Carlos, en Californie, née en 2024 des travaux de Stanford. Son TS-104 accroche cinq intégrines tumorales à la fois par un peptide polyspécifique, au lieu de viser un antigène unique comme un ADC classique, et y attache la charge cytotoxique MMAE. La FDA a autorisé l'essai de phase 1 le jour de l'annonce.
Verified
Announced on , logged by the watch of 9 September 2026.
- Operation
- Funding round
- Announced amount
- 62,5 M$
- Stage
- Series A
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Insight Partners , Medical Excellence Capital , M Ventures , Pfizer Ventures , with NFX , 2048 Ventures , Stanford University
Provenance
Source businesswire,endpoints
Logged on 9 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.